1. Introduction {#sec1-ijerph-17-05589}
===============

Currently, more than four months since declaration of the coronavirus disease 2019 (COVID-19) as a pandemic by the World Health Organization (WHO) on March 11th, 2020, more than 14 million people have been infected with the virus and more than half a million have died worldwide. Marked differences in COVID-19 mortalities have been observed in different countries. For example, the mortality per million population is till now several tens of times or even higher in Western countries, e.g., Belgium (845), the United Kingdom (UK, 664), the United States of America (USA, 426) and Germany (109), than in Asian countries, e.g., India (19), Japan (8) and China (3), as of 17 July 2020. This is quite the opposite of what was reported during the 1918--20 influenza pandemic, the so called Spanish flu, in which the population mortality was over 30-fold higher, with excess death rates observed in low-income countries, such as India, than in high-income countries, such as those in the West \[[@B1-ijerph-17-05589]\]. Higher morbidities and mortalities may be explained by easy access to diagnostic polymerase chain reaction tests (PCR-tests) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in these Western countries. In contrast, they may be underestimated in middle- and low-income countries due to low capacities of PCR-testing and poor access to health care. Alternatively, there is growing concern that racial and ethnic minority, as well as socioeconomic and biological factors may influence the high morbidity and mortality. A retrospective study of integrated health care systems suggested that Black race compared with White race, increasing age, male sex, having a greater burden of comorbidities, type of public insurance, residence in a low-income area and obesity were associated with increased odds of hospital admission \[[@B2-ijerph-17-05589]\]. On the other hand risk of in-hospital mortality increased only in aged patients and was not associated with the Black race, sex, comorbidities, obesity and other factors after multivariate adjustment \[[@B2-ijerph-17-05589]\]; this phenomenon was also confirmed in other races, i.e., Asians and Hispanics, compared with the White race \[[@B3-ijerph-17-05589],[@B4-ijerph-17-05589]\]. Moreover, since COVID-19 is an infectious disease that spreads mainly through the droplet route by close contact in dense human societies, metropolitan areas, such as New York City in the USA \[[@B5-ijerph-17-05589]\] and Lombardy in Italy \[[@B6-ijerph-17-05589]\], Paris in France \[[@B7-ijerph-17-05589]\], Sao Paulo in Brazil \[[@B8-ijerph-17-05589]\], and so on, have tended to be regional epicenters. However, associations between population dynamics, e.g., population size, density, migrants and urbanization and the morbidity/mortality of COVID-19 have not yet been well examined.

In addition to the factors listed above, several scientists proposed a hypothesis \[[@B9-ijerph-17-05589],[@B10-ijerph-17-05589],[@B11-ijerph-17-05589],[@B12-ijerph-17-05589]\] that Bacillus Calmette--Guérin (BCG) vaccination has preventive effects not only against tuberculosis, i.e., the target disease of the vaccine, but also other non-specific infectious diseases, i.e., off-target diseases such as COVID-19, through epigenetic mechanisms \[[@B13-ijerph-17-05589],[@B14-ijerph-17-05589],[@B15-ijerph-17-05589]\]. In fact, ecological studies have suggested that both COVID-19 morbidities and mortalities were less in BCG-vaccinated countries than in BCG-non-vaccinated countries \[[@B16-ijerph-17-05589],[@B17-ijerph-17-05589],[@B18-ijerph-17-05589]\]. However, because these studies only obtained data during the early phase of the pandemic, by which time the disease load had escalated in Western countries, but not yet escalated in low- and middle-income countries where BCG is given at birth and did not adjust for any potential confounders, including PCR-test number per million population, the BCG-hypothesis needs to be reexamined now, more than four months after declaration of the pandemic, since the number of PCR-confirmed COVID-19 cases are still growing in many countries. We therefore aimed to explore whether recent BCG vaccine coverage is associated with COVID-19 morbidity and/or mortality rates, using linear regression models to explore associations between the two continuous random variables adjusted for a variety of potential confounders, such as median age and body mass index (BMI) in individual countries through this ecological study.

2. Materials and Methods {#sec2-ijerph-17-05589}
========================

2.1. Ethics Statement {#sec2dot1-ijerph-17-05589}
---------------------

Institutional review board approval for this work was not sought due to the use of publicly available data obtained from open resources.

2.2. Study Design {#sec2dot2-ijerph-17-05589}
-----------------

This ecological study compared population data of each country.

2.3. Data Resources {#sec2dot3-ijerph-17-05589}
-------------------

All data were obtained from open resources: Information on total number of cases, total number of deaths and number of PCR-tests performed per million population were obtained from 'Coronavirus Update' \[[@B19-ijerph-17-05589]\], data regarding population dynamics were obtained from 'World Population Clock' \[[@B20-ijerph-17-05589]\], socioeconomic covariates were obtained from 'the United Nations database' \[[@B21-ijerph-17-05589]\], BCG vaccine coverage data were obtained from 'The BCG World Atlas' \[[@B22-ijerph-17-05589]\] and 'The global health observatory' on the WHO homepage \[[@B18-ijerph-17-05589]\] and other health related data were from the same WHO site \[[@B23-ijerph-17-05589]\]. Definitions of each of the covariates are described in the Supplement. Only countries that had data of both total deaths and BCG vaccine coverage were included for analyses in this study.

2.4. Outcomes and PCR-Tests {#sec2dot4-ijerph-17-05589}
---------------------------

The outcomes evaluated in this study were COVID-19 morbidity, i.e., total COVID-19 cases per million population and COVID-19 mortality, i.e., total COVID-19-related deaths per million population, in each country, obtained from 'Worldometer COVID-19 Data' on July 17th, 2020 \[[@B19-ijerph-17-05589]\]. Data on the total number of PCR-tests performed per million population were simultaneously obtained from the same 'Worldometer COVID-19 Data' website. PCR-test positivity was simply calculated as the total COVID-19 case number divided by the total number of PCR-tests performed in each country.

2.5. BCG Vaccine Coverage {#sec2dot5-ijerph-17-05589}
-------------------------

Recent BCG vaccine coverage was defined as the percentage of the vaccinated population among one-year-olds in each country (World Health Data Platform, the World Health Observatory, BCG-Immunization coverage estimates) \[[@B23-ijerph-17-05589]\]. For countries that have already stopped a national BCG vaccine immunization program \[[@B22-ijerph-17-05589]\], which includes a significant number of countries, their BCG vaccine coverage rate was counted as zero percent in this study.

2.6. Sixty-One Covariates {#sec2dot6-ijerph-17-05589}
-------------------------

The covariates evaluated in this study, the definitions of which are described in the [Supplement (Table S1)](#app1-ijerph-17-05589){ref-type="app"}, included: (1) Population (n); (2) yearly change in population (%); (3) net change in population (n); (4) population density (n/km^2^); (5) land area (km^2^); (6) net number of migrants (n); (7) fertility rate (n); (8) median age (years); (9) urban population percentage (%); (10) world share (%); (11) population between age 0 to 14 years (%); (12) population ≥ 60 years of age (%); (13) population ≥ 70 years of age (%); (14) gross domestic product (GDP) (million US dollars); (15) GDP per capita (US dollars); (16) total unemployment rate (%); (17) male unemployment rate (%); (18) female unemployment rate (%); (19) total labor force participation rate (%); (20) male labor force participation rate (%); (21) female labor force participation rate (%); (22) annual incidence of tuberculosis per 100,000 population (n); (23) international health regulation (IHR) score (%); (24) universal health coverage (UHC) index; (25) hospital beds (n) per 10,000 population; (26) medical doctors (n) per 10,000 population; (27) nursing midwifery (n) per 10,000 population; (28) licensed qualified anesthesiologists who usually cover management of intensive care units actively working (n) per 10,000 population; (29) total expenditure on health as a percentage of GDP (%); (30) population with household expenditures on health greater than 10% of total household expenditure or income (%); (31) prevalence of high blood pressure (systolic ≥ 140 or diastolic ≥ 90 mmHg) (%); (32) prevalence of elevated fasting blood glucose levels (≥7.0 mmol/L or on anti-diabetic medication); (33) prevalence of elevated total cholesterol levels (≥5.0 mmol/L) (%); (34) mean BMI (body weight \[kg\]/height^2^ \[m^2^\]); (35) prevalence of obesity among adults, BMI ≥ 30 kg/m^2^ (%); (36) prevalence of 'overweight' people among adults, BMI ≥ 25 kg/m^2^ (%); (37) alcohol drinking, total per capita (≥15 years of age) consumption (in liters of pure alcohol over a calendar year); (38) prevalence of smoking any tobacco product among males aged ≥ 15 years (%); (39) prevalence of smoking any tobacco product among females aged ≥ 15 years (%); (40) prevalence of insufficient physical activity among adults aged ≥ 18 years (%); (41) estimated population-based prevalence of depression (%); (42) neonatal mortality rate (n per 1000 live births); (43) infantile mortality rate (n per 1000 live births); (44) under-five mortality rate (probability of dying by the age of 5 years per 1000 live births); (45) mortality rate for 5--14-year-olds (probability of dying per 1000 children aged 5--14 years); (46) adult mortality rate (probability of dying between 15 and 60 years of age per 1000 population); (47) probability of dying between age 30 and exact age 70 years from any of the following causes: cardiovascular disease, cancer, diabetes or chronic respiratory disease; (48) life expectancy at birth (years); (49) life expectancy at age 60 years (years); (50) healthy life expectancy (HALE) at birth (years); (51) HALE at age 60 years (years); (52) death due to chronic obstructive pulmonary disease (%); (53) death due to ischemic heart disease (%); (54) death due to lower respiratory infections (%); (55) death due to stroke (%); (56) death due to tracheal, bronchial and lung cancers (%); (57) total of (52) to (56) as ambient and household air pollution-attributable death rate (n per 100,000 population); and (58) annual mean concentration of particulate matter less than 2.5 microns in diameter (PM~2.5~) \[µg/m^3^\] in urban areas; and (59) coverage rate with the first dose of a measles-containing-vaccine (MCV1) among one-year-olds (%) as well as (60) recent BCG coverage and (61) PCR-tests number.

2.7. Statistics {#sec2dot7-ijerph-17-05589}
---------------

### Linear Regression Models

For preprocessed data, outcomes, i.e., morbidity and mortality per million population were transformed to the common logarithm (log10) to adjust for normality of the distribution, which was verified by means of kurtosis tests. When the number of total deaths was zero, these were changed to 0.01 per million population, because zero cannot be transformed to the common logarithm. Variance inflation factor (VIF) was used to detect the presence of multicollinearity. Only one variable among biologically similar variables, e.g., 'median age (years)', '≥ 60 years of age (%)' and '≥ 70 years of age', was selected to maximize adjusted R^2^ in the multi-linear regression models to avoid the influence of collinearity. If the variance inflation factor (VIF) of certain covariates was more than 10, then the covariates were avoided in multivariate analyses because of a collinearity issue. Multiple linear regression models were used to screen potential risk or preventive factors associated with morbidity by adjusting for PCR-test numbers transformed to the common logarithm (log10) and those associated with mortality were screened by adjusting for PCR-test numbers and morbidity per million population. Considering type I error due to a multiple testing, the significance level of alfa was set as *p* \< 0.001. Then, all the screened factors were assessed in a multi-linear regression model to determine significant factors with *p* \< 0.05 as the cutoff point. Each model was evaluated by adjusted R^2^ as a coefficient of determination. Pearson's correlation coefficient for variables with normal distributions or Spearman's rank correlation for variables with non-normal distributions, represented as rho, was used to quantify the strengths of associations between morbidity, mortality and significant factors determined by the final models, as: absolute value of rho ≥ 0.5: very strong; rho ≥ 0.4: strong; 0.4 \> rho ≥ 0.2: moderate; and rho \< 0.2: weak associations. Data were analyzed using Stata version 14.0 software (StataCorp LP, College Station, TX, USA).

3. Results {#sec3-ijerph-17-05589}
==========

3.1. Variability of COVID-19 Morbidity and Mortality across 173 Countries {#sec3dot1-ijerph-17-05589}
-------------------------------------------------------------------------

A total of 173 countries that had data of both total COVID-19 deaths and BCG vaccine coverage were included for analyses in this study. The 20 countries with highest and lowest COVID-19 morbidities ([Table 1](#ijerph-17-05589-t001){ref-type="table"}) and mortalities ([Table 2](#ijerph-17-05589-t002){ref-type="table"}), as well as their PCR-test rate per million population are shown below. Marked differences in morbidities and mortalities were observed among these countries, ranging from 1 (Papua New Guinea) to 37,566 (Qatar) and from 0 (Vietnam, etc.) to 845 (Belgium), respectively. Six and thirteen countries that do not have a BCG national vaccine program at present (indicated with bold and mark "∫") were included in the 20 countries with the highest COVID-19 morbidity and mortality, respectively.

Histograms of morbidities and mortalities were drawn as normal density plots ([Figure 1](#ijerph-17-05589-f001){ref-type="fig"}). Although the histograms of morbidity and mortality were skewed to the right, they followed a normal distribution by transformation with the common logarithm (log10).

3.2. Associations between Morbidity, Mortality and PCR-Tests per Million Population {#sec3dot2-ijerph-17-05589}
-----------------------------------------------------------------------------------

First, associations represented by rho and VIF between morbidity (*n* = 173), mortality (*n* = 173) and PCR-tests (*n* = 155) are shown ([Figure 2](#ijerph-17-05589-f002){ref-type="fig"}A). These three variables were predicted to have very strong and positive associations with each other. However, VIFs were less than 2 among these three factors. Multicollinearity is considered to be present when the VIF is higher than 5 to 10 \[[@B24-ijerph-17-05589]\]. Thus, any variable with a VIF \< 5.0 was considered for inclusion in multiple linear regression analyses. Considering the number of PCR-tests per million population may exhibit associations with morbidity, adjustment was performed for the PCR-test number in every analysis when screening for the risk factors of COVID-19 morbidity per million population ([Figure 2](#ijerph-17-05589-f002){ref-type="fig"}B). Considering morbidities and the number of PCR-tests per million population may exhibit associations with mortality, adjustment was performed for the morbidity and PCR-test number in every analysis when screening for the risk factors of COVID-19 mortality per million population ([Figure 2](#ijerph-17-05589-f002){ref-type="fig"}C).

Since fewer PCR-tests may underestimate morbidity and mortality, the association between mortality as the outcome and morbidity as the exposure was adjusted for number of PCR-tests performed ([Table 3](#ijerph-17-05589-t003){ref-type="table"}). In this multiple regression analysis, higher morbidity was associated with higher mortality, whereas more PCR-tests were associated with lower mortality.

Evaluation of the association between PCR-test positivity and mortality, shown as a scatter plot, indicated a very strong association between them (rho = 0.54) ([Figure 3](#ijerph-17-05589-f003){ref-type="fig"}). Countries with higher PCR-positivity rates tended to have higher mortality rates. PCR-test positivity rates of countries where no deaths due to COVID-19 were observed were less than 3.5%. Minimum positivity and no deaths were observed in Vietnam.

3.3. Screening Factors Associated with Morbidity {#sec3dot3-ijerph-17-05589}
------------------------------------------------

Among the 59 covariates, plus BCG vaccine coverage and PCR-testing rate, i.e., a total of 61 factors, 'urban population' and 'insufficient physical activity' were significantly (*p* \< 0.001) associated with morbidity after adjustment for PCR-test rate ([Table 4](#ijerph-17-05589-t004){ref-type="table"}). Next, these two significant factors were used in a multi-linear regression model to eliminate confounding ([Table 5](#ijerph-17-05589-t005){ref-type="table"}). As a result, 'urban population' (*p* = 0.02) and 'insufficient physical activity' (*p* = 0.01) remained significant factors associated with COVID-19 morbidity, even after adjustment for PCR-tests. The adjusted R^2^ was 0.5037.

The association between 'urban population' and morbidity, demonstrated below as a scatter plot, showed a very strong association (rho = 0.55) ([Figure 4](#ijerph-17-05589-f004){ref-type="fig"}).

The association between 'insufficient physical activity' and morbidity, demonstrated below as a scatter plot, also showed a very strong association (rho = 0.52) ([Figure 5](#ijerph-17-05589-f005){ref-type="fig"}).

COVID-19-related morbidity rates per million population on July 17th were transformed to the common logarithm (log10) in the graph. Countries that had never had or that had stopped a national program of BCG vaccination are indicated in red, while countries that currently follow a national BCG vaccine program are indicated in black. Selected country's name was shown using three-letter country codes.

3.4. Screening Factors Associated with Mortality {#sec3dot4-ijerph-17-05589}
------------------------------------------------

Among the 58 covariates evaluated, plus BCG vaccine coverage, adjusted for morbidity and PCR-tests, age-related factors, i.e., median age, ≥60 years of age (%) and ≥70 years of age (%), were significantly (*p* \< 0.001) associated with mortality ([Table 4](#ijerph-17-05589-t004){ref-type="table"}). Since these three age-related factors had collinearity for mortality, '≥ 60 years of age' was selected to maximize adjusted R^2^ of the multi-linear regression models. Moreover, 'BCG vaccine coverage', 'Elevated total cholesterol levels' and 'Life expectancy at 60 years of age', were also significant (*p* \< 0.001) factors associated with mortality. Next, these significant factors were used in a multi-linear regression model to eliminate confounding ([Table 6](#ijerph-17-05589-t006){ref-type="table"}). As a result, '≥60 years of age' (*p* \< 0.001) and 'BCG vaccine coverage' (*p* = 0.002) remained significant factors associated with COVID-19 mortality, even after adjustment for morbidity and PCR-tests. The adjusted R^2^ was 0.8254.

Evaluation of the association between 'median age' and mortality, demonstrated as a scatter plot, showed a very strong association between these two variables (rho = 0.54) ([Figure 6](#ijerph-17-05589-f006){ref-type="fig"}). Countries with a larger population ≥ 60 years of age (%) showed a tendency toward a higher mortality rate.

Finally, evaluation of the association between 'BCG vaccine coverage' and mortality, demonstrated as a scatter plot, indicated a moderately negative association (rho = −0.29) ([Figure 7](#ijerph-17-05589-f007){ref-type="fig"}). Countries with higher BCG vaccine coverage showed a tendency toward lower mortality. Additionally, COVID-19 mortality rates did not have significant associations with BCG strain, e.g., Tokyo 172. Moreover, there were no significant associations between mortality and either the year of stopping or introducing a national BCG vaccine program (data not shown).

4. Discussion {#sec4-ijerph-17-05589}
=============

Among the variety of parameters abstracted from open resources, 'BCG vaccine coverage' had a significant association with COVID-19 mortality, even after adjusting for morbidity, PCR-tests, age, universal health coverage, numbers of medical doctors, elevated total cholesterol and healthy life expectancy. On the other hand, BCG vaccination was not associated with COVID-19 morbidity. The main results of this study are consistent with a very recent article demonstrating that every 10% increase in the BCG index was associated with a 10% reduction in COVID-19 mortality \[[@B25-ijerph-17-05589]\]. Moreover, a retrospective cohort study suggested that BCG-vaccinated individuals were less likely to require hospital admission during the disease course \[[@B26-ijerph-17-05589]\]. In contrast to BCG, coverage of the measles vaccine, which is also considered to induce heterologous protection against infections through long-term boosting of innate immune responses \[[@B9-ijerph-17-05589]\], showed no association with the morbidity and mortality of COVID-19, which was also consistent with a very recent article showing a significant low risk of COVID-19 mortality in countries with higher BCG vaccine coverage, but not with measles vaccine coverage \[[@B27-ijerph-17-05589]\].

Moreover, SARS-CoV-2 is a single-stranded positive-sense RNA virus and the BCG vaccine has been shown in controlled trials to reduce the severity of infections by other viruses with such a structure \[[@B9-ijerph-17-05589]\]. For example, the BCG vaccine reduced yellow fever vaccine viremia by 71% in volunteers in the Netherlands \[[@B28-ijerph-17-05589]\]. However, some countries with a current national BCG vaccination policy have high mortality rates. Plausible reasons for this discrepancy may be: (1) low coverage of BCG vaccination in these countries (% coverage--mortality per million population), e.g., Ireland (18%---354); Portugal (32%---165); and Greece (50%---19): (2) late introduction of BCG vaccine program (year of introduction--mortality per million population), e.g., Iran, (1984--162): (3) oral delivery of the BCG vaccine, e.g., Brazil retained oral delivery of the vaccine until 1977: (4) UK administered the vaccine to older children (12 to 13 years of age) and (5) connection with endemic country by land, e.g., Mexico, Panama, Peru and Chile.

Higher morbidity, but fewer PCR-tests, were associated with higher mortality. Moreover, higher PCR-test positivity was associated with higher mortality, which was consistent with the report by Hisaka et al. \[[@B29-ijerph-17-05589]\]. Expanding application of PCR-tests not only to typical symptomatic cases, but also to mild or asymptomatic cases and to those who had close contact with patients, may decrease the PCR-test positivity rate. Thus, enhancing the capacity of PCR-testing may enable identification of cases, so that appropriate measures can be taken to prevent them spreading SARS-CoV-2 to others at home, at their work place or at events of mass gatherings.

In this study, the covariate of 'urban population' and 'insufficient physical inactivity' had a strong and positive association with morbidity, but not with mortality. People living in urban areas tend to have close contact with a greater number of people per day than those in rural areas, independent of age. A report on 4103 patients with COVID-19 in New York City found that obesity, which may strongly depend on the balance between physical activity and diet, was one of the clinical features leading to hospital admission \[[@B30-ijerph-17-05589]\]. On the other hand, older age was associated with higher mortality, which is consistent with previous articles \[[@B2-ijerph-17-05589],[@B3-ijerph-17-05589],[@B4-ijerph-17-05589]\]. From this study, the risk factors for morbidity seem to be different from those associated with mortality, suggesting that factors related to susceptibility may be different from those related to disease severity.

There are several limitations to this study. First, although we selected 61 covariates in this study, we did not evaluate range and timing of non-pharmaceutical interventions, e.g., school closures, workplace closures, cancellation of public events, restrictions on public gatherings, stay-at-home restrictions, restrictions on internal movement, international travel controls, etc., all of which would also have had significant effects on COVID-19-related morbidity and mortality. Therefore, the present study results are burdened with an extreme error. Second, the study design was ecological. Therefore, the outcome of this work should be considered highly limited, with a potential risk of high bias. Consequently, only the hypothesis that BCG vaccination mitigates COVID-19 mortality can be proposed here; cohort or case--control studies and randomized clinical trials, similar to the BCG--CORONA study \[[@B31-ijerph-17-05589]\], are required to test this hypothesis. Third, the COVID-19 pandemic is still ongoing, although we have confirmed the results using the latest data. However, the results may be different a few months from now. Fourth, it is clear that an extremely large number of covariates, i.e., 61, were selected for the limited number of 173 countries. This sample size could allow use of a maximum of 10 covariates in multiple regression analysis. Therefore, significant (*p* \< 0.001) variables were at first screened after adjustment for PCR-tests and morbidity ([Table 4](#ijerph-17-05589-t004){ref-type="table"}). Then, multivariable linear regression using the screened variables were performed after adjustment for PCR-tests and morbidity ([Table 5](#ijerph-17-05589-t005){ref-type="table"} for morbidity and [Table 6](#ijerph-17-05589-t006){ref-type="table"} for mortality). Fifth, mortality in each country should be compared with excess deaths whether these two do not make a big difference. Sixth, the definition of COVID-19 cases may differ by country, e.g., including PCR confirmed, but asymptomatic cases and pneumonia cases with negative PCR-tests. Seventh, there were still residual confounders even after adjustment for PCR-tests.

5. Conclusions {#sec5-ijerph-17-05589}
==============

Our results suggest the hypothesis that greater BCG vaccine coverage may reduce the risk of deaths due to COVID-19, which needs to be further studied by observational studies and confirmed by randomized clinical trials.
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![Histograms of morbidities and mortalities drawn as a normal density plot. (**A**) Morbidity per million; (**B**) mortality per million; (**C**) log10 transformed morbidity; and (**D**) log10 transformed mortality.](ijerph-17-05589-g001){#ijerph-17-05589-f001}

![(**A**) Associations between morbidity, mortality and PCR-tests. Either Pearson's correlation coefficient or Spearman's rank correlation was applied to calculate rho; (**B**) associations between morbidity and risk factors were adjusted for PCR-tests per million population (log10); (**C**) associations between mortality and risk factors were adjusted for morbidity (log10) and PCR-tests (log10) per million population.](ijerph-17-05589-g002){#ijerph-17-05589-f002}

![Scatter plot showing the association between PCR-test positivity and mortality. Mortality per million population and PCR-test positivity rates (%) on 17 July 2020 were transformed to the common logarithm (log10) in the graph. Since the variable of 'PCR-test positivity (log10)' showed a normal distribution, Pearson's correlation coefficient was applied to calculate rho, to quantify the strength of the association. Countries that never had or stopped a national BCG vaccine program are indicated in red, while countries with current national BCG vaccine programs are indicated in black. Selected country names are shown using three-letter country codes.](ijerph-17-05589-g003){#ijerph-17-05589-f003}

![Scatter plot showing the association between urban population and COVID-19 morbidity rates. COVID-19-related morbidity rates per million population on 17 July 2020 were transformed to the common logarithm (log10) in the graph. Since the variable of 'urban population' showed a non-normal distribution, Spearman's rank correlation was applied to calculate rho, to quantify the strength of the association. Countries that had never had or that had stopped a national program of BCG vaccination are indicated in red, while countries that currently follow a national BCG vaccine program are indicated in black. Selected country names are shown using three-letter country codes.](ijerph-17-05589-g004){#ijerph-17-05589-f004}

![Scatter plot showing the association between insufficient physical activity and COVID-19 morbidity rates.](ijerph-17-05589-g005){#ijerph-17-05589-f005}

![Scatter plot showing the association between ≥60 years of age (%) of the population and mortality rate. Mortalities per million population on 17 July 2020 transformed to the common logarithm (log10) are presented in the graph. Since the variable of 'percentage of population ≥ 60 years of age (%)' showed a non-normal distribution, Spearman's rank correlation was applied to calculate rho, to quantify the strength of the association. Countries that had never had or that had stopped their national BCG vaccine program are indicated in red, while countries that currently follow a national BCG vaccine program are indicated in black. Selected country names are shown using three-letter country codes.](ijerph-17-05589-g006){#ijerph-17-05589-f006}

![Scatter plot showing the association between COVID-19-related mortality and BCG vaccine coverage. Mortalities per million population on 17 July 2020 are transformed to the common logarithm (log10) in the graph. Since the variable of 'BCG vaccine coverage' showed a non-normal distribution, Spearman's rank correlation was applied to calculate rho, to quantify the strength of the association. Selected country names are shown using three-letter country codes.](ijerph-17-05589-g007){#ijerph-17-05589-f007}

ijerph-17-05589-t001_Table 1

###### 

Twenty countries with the highest and lowest COVID-19 morbidity rates and their PCR-test rate per million population.

  The Highest 20 Countries   The Lowest 20 Countries                                                                    
  -------------------------- ------------------------- -------- --------- ----- ---------------------------------- ---- ------
  1                          Qatar                     37,566   153,380   173   Papua New Guinea                   1    798
  2                          Chile                     16,927   70,696    172   Lao People's Democratic Republic   3    2990
  3                          Kuwait                    13,496   105,205   171   Vietnam                            4    2824
  4                          Oman                      12,244   50,512    170   Myanmar                            6    1770
  5                          Panama                    11,406   40,384    169   United Republic of Tanzania        9    
  6                          Armenia                   11,324   47,718    168   Cambodia                           10   2896
  7                          **Andorra ^∫^**           11,156   48,531    167   Angola                             18   304
  8                          **USA ^∫^**               11,118   137,544   166   Timor-Leste                        18   1189
  9                          Peru                      10,355   60,747    165   Taiwan                             19   3319
  10                         Brazil                    9464     23,098    164   Uganda                             23   5133
  11                         **Luxembourg ^∫^**        8438     502,852   163   Burundi                            23   563
  12                         Singapore                 8053     172,506   162   Syrian Arab Republic               27   
  13                         **Sweden ^∫^**            7610     67,495    161   Fiji                               29   4461
  14                         Saudi Arabia              6983     71,623    160   Gambia                             32   1477
  15                         Belarus                   6945     123,003   159   Mozambique                         44   1360
  16                         **Spain ^∫^**             6543     128,893   158   Niger                              45   276
  17                         UAE                       5673     436,262   157   Thailand                           46   8647
  18                         South Africa              5464     39,182    156   Burkina Faso                       50   
  19                         **Belgium ^∫^**           5438     121,891   155   Yemen                              52   4
  20                         Maldives                  5234     118,769   154   Chad                               54   

\* Numbers per million population, USA---United States of America, UAE---United Arab Emirates. Bold letters with mark "∫" mean no recent national BCG vaccination program for all.

ijerph-17-05589-t002_Table 2

###### 

Twenty countries with the highest and lowest COVID-19 mortality rates and their PCR-test rates per million population.

  The Highest 20 Countries   The Lowest 20 Countries                                                                   
  -------------------------- ------------------------- ----- --------- ----- ---------------------------------- ------ --------
  1                          **Belgium ^∫^**           845   121,891   173   Papua New Guinea                   0      798
  2                          **Andorra ^∫^**           673   48,531    172   Lao People's Democratic Republic   0      2990
  3                          **UK ^∫^**                664   186,591   171   Vietnam                            0      2824
  4                          Spain                     608   128,893   170   Cambodia                           0      2896
  5                          **Italy ^∫^**             579   100,954   169   Timor-Leste                        0      1189
  6                          **Sweden ^∫^**            554   67,495    168   Uganda                             0      5133
  7                          **France ^∫^**            462   39,868    167   Fiji                               0      4461
  8                          **USA ^∫^**               426   137,544   166   Eritrea                            0      
  9                          Peru                      382   60,747    165   Mongolia                           0      8688
  10                         Chile                     381   70,696    164   Bhutan                             0      51,107
  11                         Brazil                    361   23,098    163   Saint Lucia                        0      11,494
  12                         **Netherlands ^∫^**       358   44,588    162   Greenland                          0      90,957
  13                         **Ireland ^∫^**           354   107,707   161   Dominica                           0      11,820
  14                         **Ecuador ^∫^**           295   11,023    160   Saint Vincent and the Grenadines   0      10,932
  15                         Mexico                    286   5958      159   Saint Kitts and Nevis              0      13,248
  16                         **Canada ^∫^**            234   88,515    158   Seychelles                         0      
  17                         **Switzerland ^∫^**       227   81,825    157   Burundi                            0.08   563
  18                         Panama                    227   40,384    156   Myanmar                            0.1    1770
  19                         Armenia                   205   47,718    155   Taiwan                             0.3    3319
  20                         North Macedonia           192   38,771    154   Mozambique                         0.3    1360

\* Numbers per million population, USA---United States of America, UK---United Kingdom, VCT---Saint Vincent and the Grenadines. Bold letters with mark "∫" mean no recent national BCG vaccination program for all.
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###### 

Association between mortality as the outcome and morbidity as the exposure, adjusted for number of PCR-tests performed.

  Variable                                   Coef.    Std. Err.   *p*-Value   95% CI             Adjusted R^2^
  ------------------------------------------ -------- ----------- ----------- ------------------ ---------------
  Morbidity per million population (log10)   1.395    0.083       \<0.001     1.232 to 1.558     0.7067
  PCR-tests per million population (log10)   −0.241   0.086       0.005       −0.416 to −0.075   

Coef.---Coefficient; Std. Err.---Standard Error; 95% CI---95% confidence interval.
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###### 

Associations between COVID-19 morbidity and mortality per million population and world data for each country.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                                                            *N* \* ^3^   Median, IQR                Min (Country)\                         Morbidity \* ^1^\   Mortality \* ^2^\
                                                                                                                                                                              Max (Country)                          Adjusted R^2^       Adjusted R^2^
  ----------------------------------------------------------------------------------------------------------------------------------- ------------ -------------------------- -------------------------------------- ------------------- -------------------
  Population, *n*                                                                                                                     173          1.02 × 10^7^\              3.9 × 10^5^ (Monaco)\                  0.3732              0.7120
                                                                                                                                                   3.5 × 10^6^--3.3 × 10^7^   1.4 × 10^9^ (China)                                        

  Yearly change (%)                                                                                                                   173          1.11\                      −1.35 (Lithuania)\                     0.3822              0.7172
                                                                                                                                                   0.35--1.96                 3.84 (Niger)                                               

  Net change, *n*                                                                                                                     173          89,516\                    −383,840 (Japan)\                      0.3713              0.7073
                                                                                                                                                   8516--447,563              1.40 × 10^7^ (India)                                       

  Population density, *n*/km^2^                                                                                                       173          83\                        0 (Greenland)\                         0.3723              0.7048
                                                                                                                                                   34--167                    26,337 (Monaco)                                            

  Land area, km^2^                                                                                                                    173          183,630\                   1 (Monaco)\                            0.3726              0.7079
                                                                                                                                                   35,410--581,795            1.6 × 10^7^ (Russia)                                       

  Migrants, *n* (net)                                                                                                                 168          −1590\                     −653,249 (Venezuela))\                 0.3885              0.7460
                                                                                                                                                   −16,026--14,440.5          954,806 (USA)                                              

  Fertility rate, *n*                                                                                                                 168          2.27\                      1.11 (Korea)\                          0.3784              0.7516
                                                                                                                                                   1.71--3.65                 6.95 (Niger)                                               

  **Urban population (%)**                                                                                                            **168**      **60**\                    **13 (Papua New Guinea)**\             **0.4246 \***       0.7243
                                                                                                                                                   **43--78**                 **98 (Belgium)**                                           

  World share (%)                                                                                                                     173          0.1\                       0 (Saint Lucia, etc.)\                 0.3732              0.7120
                                                                                                                                                   0.05--0.4                  18.5 (China)                                               

  Age                                                                                                                                                                                                                                    

  **Median age, years**                                                                                                               **168**      **30**\                    **15 (Niger)**\                        0.3787              **0.7811 \***
                                                                                                                                                   **21.5--39**               **48 (Japan)**                                             

  0 to 14 years of age (%)                                                                                                            165          26.8\                      12.3 (Niger)\                          0.3789              0.7574
                                                                                                                                                   17.6--37.3                 49.8 (Singapore)                                           

  **≥ 60 years of age (%)**                                                                                                           **165**      **9.72**\                  **2.80 (UAE)**\                        0.3802              **0.7986 \***
                                                                                                                                                   **5.30--20.48**            **34.01 (Japan)**                                          

  **≥ 70 years of age (%)**                                                                                                           **162**      **3.41**\                  **0.53 (UAE)**\                        0.3818              **0.8027 \***
                                                                                                                                                   **2.03--9.17**             **18.49 (Japan)**                                          

  Economy                                                                                                                                                                                                                                

  GDP, million US dollars                                                                                                             170          40,729\                    393 (Sao Tome)\                        0.3701              0.7095
                                                                                                                                                   11,135--223,780            1.90 × 10^7^ (USA)                                         

  GDP per capita, US dollars                                                                                                          170          51.4\                      104 (Somalia)\                         0.3722              0.7051
                                                                                                                                                   1534--15,347               165,421 (Monaco)                                           

  Total unemployment rate (%)                                                                                                         164          5.85\                      0.1 (Qatar)\                           0.3933              0.7436
                                                                                                                                                   3.75--9.40                 28.2 (Lesotho)                                             

  Male unemployment rate (%)                                                                                                          164          5.5\                       0 (Qatar)\                             0.3905              0.7433
                                                                                                                                                   3--8.5                     26 (Eswatini)                                              

  Female unemployment rate (%)                                                                                                        164          7\                         0 (Niger)\                             0.4078              0.7435
                                                                                                                                                   4--12                      38 (Syria)                                                 

  Total labor force participation rate (%)                                                                                            164          62\                        38 (Yemen)\                            0.3939              0.7597
                                                                                                                                                   55--68                     87 (Qatar)                                                 

  Male labor force participation rate (%)                                                                                             164          73\                        45 (Moldova)\                          0.3809              0.7602
                                                                                                                                                   66.5--79                   95 (Qatar)                                                 

  Female labor force participation rate (%)                                                                                           164          53.5\                      6 (Yemen)\                             0.4216              0.7479
                                                                                                                                                   45--60.5                   84 (Rwanda)                                                

  National BCG vaccine program                                                                                                                                                                                                           

  Annual incidence of tuberculosis, *n*/100,000                                                                                       164          57\                        2 (UAE)\                               0.3693              0.7053
                                                                                                                                                   17--176                    834 (South Africa)                                         

  **Recent BCG vaccine coverage (%)**                                                                                                 **173**      **93**\                    **0 (Italy, etc.)**\                   0.3814              **0.7415 \***
                                                                                                                                                   **81--98**                 **99 (Japan, etc.)**                                       

  Global health observatory                                                                                                                                                                                                              

  Health policy                                                                                                                                                                                                                          

  International Health Regulations score                                                                                              170          64\                        17 (Central African Republic)\         0.3817              0.7205
                                                                                                                                                   48 to 82                   99 (Canada, Russia)                                        

  **Universal health coverage index**                                                                                                 **166**      **0.41**\                  **0.17 (Saint Lucia)**\                0.3812              **0.7644 \***
                                                                                                                                                   **0.36 to 0.47**           **0.70 (Peru)**                                            

  Total expenditure on health as a percentage of gross domestic product                                                               169          6.38\                      1.48 (Timor-Leste)\                    0.3977              0.7283
                                                                                                                                                   4.76--8.43                 17.14 (USA)                                                

  Population with household expenditures on health greater than 10% of total household expenditure/income (%)                         146          6.56\                      0.20 (Gambia)\                         0.3956              0.7906
                                                                                                                                                   3.13--12.76                54.2 (Sierra Leone)                                        

  Medical personnel                                                                                                                                                                                                                      

  Hospital beds, *n*/10,000 population                                                                                                164          21\                        1 (Mali)\                              0.3718              0.7409
                                                                                                                                                   11--40                     134 (Japan)                                                

  **Medical doctors, *n*/10,000 population**                                                                                          **169**      **15.7**\                  **0.1 (Tanzania)**\                    0.3800              **0.7351 \***
                                                                                                                                                   **3.3--29.8**              **84.2 (Cuba)**                                            

  Nursing and midwifery personnel, *n*/10,000 population                                                                              169          26.6\                      0.06 (Cameroon)\                       0.3823              0.7203
                                                                                                                                                   9.4--64.4                  201.6 (Monaco)                                             

  Licensed qualified anesthesiologists actively working, *n*                                                                          141          250\                       0 (Congo)\                             0.3904              0.6924
                                                                                                                                                   18--1511                   194,634 (China)                                            

  Health biomarkers                                                                                                                                                                                                                      

  High blood pressure (SBP \> 140 OR DBP \> 90) (crude estimate) (%)                                                                  167          23\                        13 (Peru)\                             0.4091              0.7199
                                                                                                                                                   20--25                     41 (Croatia)                                               

  Elevated fasting blood glucose (\>7.0 mmol/L or on medication) (crude estimate) (%)                                                 167          8.1\                       2.6 (Burundi)\                         0.4069              0.7162
                                                                                                                                                   5.9--9.7                   16.6 (Fiji)                                                

  E**levated total cholesterol (≥5.0 mmol/L or 193 mg/dL)**\                                                                          **167**      **37.6**\                  **14.8 (Niger)**\                      0.4070              **0.7401 \***
  **(crude estimate) (%)**                                                                                                                         **25.2--52.5**             **69.7 (Denmark)**                                         

  BMI                                                                                                                                                                                                                                    

  Mean BMI, kg/m^2^                                                                                                                   167          26.2\                      20.5 (Ethiopia)\                       0.4233              0.7102
                                                                                                                                                   23.4--27.2                 30.0 (Saint Lucia)                                         

  BMI ≥ 30 kg/m^2^ (%)                                                                                                                167          19.9\                      2.1 (Vietnam)\                         0.4393              0.7135
                                                                                                                                                   7.5--25.7                  37.3 (USA)                                                 

  BMI ≥ 25 kg/m^2^ (%)                                                                                                                167          53.5\                      17.9 (Timor-Leste)\                    0.4454              0.7204
                                                                                                                                                   27.8--62.2                 72.1 (Kuwait)                                              

  Alcohol drinking, total consumption per capita among persons aged ≥ 15 years, liters of pure alcohol over a calendar year           168          6.4\                       0 (Bangladesh)\                        0.3834              0.7191
                                                                                                                                                   2.6--9.8                   15.2 (Moldova)                                             

  Prevalence of smoking any tobacco product among males aged ≥15 years (%)                                                            119          32\                        9 (Ethiopia)\                          0.4410              0.8006
                                                                                                                                                   23--44                     76 (Indonesia)                                             

  Prevalence of smoking any tobacco product among females aged ≥ 15 years (%)                                                         119          8\                         0 (Niger)\                             0.3932              0.8192
                                                                                                                                                   3--19                      40 (Serbia)                                                

  **Prevalence of insufficient physical activity among adults aged ≥ 15 years (crude estimate) (%)**                                  **143**      **28.7**\                  **5.0 (Uganda)**\                      **0.4984 \***       0.7270
                                                                                                                                                   **19.0--36.2**             **65.3 (Kuwait)**                                          

  Estimated population-based prevalence of depression (%)                                                                             166          4.4\                       3.0 (Papua New Guinea)\                0.4062              0.7486
                                                                                                                                                   4.0--5.0                   6.3 (Ukraine)                                              

  Mortality according to age group                                                                                                                                                                                                       

  Neonatal mortality rate, *n* per 1000 live births                                                                                   170          9.6\                       0.9 (Japan)\                           0.3811              0.7234
                                                                                                                                                   3.5--21.0                  42.0 (Pakistan)                                            

  Infantile mortality rate, *n* per 1000 live births                                                                                  170\         14.0\                      1.4 (Finland)\                         0.3810              0.7507
                                                                                                                                                   5.9--34.9                  84.5 (Central African Republic)                            

  Under-five mortality rate, probability of dying by age 5/1000 live births                                                           170          14.4\                      1.7 (Finland)\                         0.3813              0.7145
                                                                                                                                                   7.0--44.2                  121.5 (Somalia)                                            

  Mortality rate for 5--14-year-olds, *n*/1000 children aged 5--14 years                                                              168          2.8\                       0.4 (Luxembourg)\                      0.3781              0.7117
                                                                                                                                                   1.5--8.6                   37.3 (Niger)                                               

  Adult mortality rate, probability of dying between 15 and 60 years of age/1000 population                                           167          150\                       49 (Switzerland)\                      0.3812              0.7377
                                                                                                                                                   96--224                    484 (Lesotho)                                              

  Probability of dying between age 30 and exact age 70 from cardiovascular disease, cancer, diabetes or chronic respiratory disease   166          18.4\                      7.8 (Korea)\                           0.3886              0.7061
                                                                                                                                                   14.7--22.6                 30.6 (Yemen)                                               

  Life expectancy at birth, years                                                                                                                                                                                                        

  At birth                                                                                                                            166          73.4\                      52.9 (Lesotho)\                        0.3806              0.7600
                                                                                                                                                   65.3--81.5                 84.2 (Japan)                                               

  At age 60 years                                                                                                                     166          19.6\                      13.4 (Sierra Leone)\                   0.3838              0.7630
                                                                                                                                                   17.2--22.1                 26.4 (Japan)                                               

  Healthy life expectancy (HALE), years                                                                                                                                                                                                  

  At birth                                                                                                                            166          65.3\                      44.9 (Central African Republic)\       0.3795              0.7599
                                                                                                                                                   57.5--68.1                 76.2 (Singapore)                                           

  **At age 60 years**                                                                                                                 **166**      **14.8**\                  **10.3 (Sierra Leone)**\               0.3825              **0.7652 \***
                                                                                                                                                   **13.0--17.1**             **21.0 (Singapore)**                                       

  Disease-specific mortality                                                                                                                                                                                                             

  Chronic obstructive pulmonary disease                                                                                               166          6.13.9--8.3                0.6 (Qatar)\                           0.3975              0.7436
                                                                                                                                                                              36.8 (India)                                               

  Ischemic heart disease                                                                                                              166          21.5\                      4.9 (Brunei Darussalam)\               0.3789              0.7431
                                                                                                                                                   13.4--35.2                 106.9 (Georgia)                                            

  Lower respiratory infections                                                                                                        166          8.2\                       0.22 (Finland)\                        0.3791              0.7455
                                                                                                                                                   3.7--31.6                  130.3 (Chad)                                               

  Stroke                                                                                                                              166          10.2\                      1.4 (Qatar)\                           0.3963              0.7726
                                                                                                                                                   5.6--16.6                  49.3 (Georgia)                                             

  Tracheal, bronchial, lung cancers                                                                                                   166          1.8\                       0.2 (Niger)\                           0.3971              0.7541
                                                                                                                                                   0.8--4.2                   20.5 (China)                                               

  Air pollution                                                                                                                                                                                                                          

  Ambient and household air pollution attributable death rate /100,000 population                                                     166          65.9\                      8.5 (Georgia)\                         0.3861              0.7427
                                                                                                                                                   38.5--97.8                 184 (Brunei Darussalam)                                    

  Concentrations of fine particulate matter (PM~2.5~)                                                                                 170          21.1\                      5.7 (New Zealand)\                     0.3940              0.7210
                                                                                                                                                   14.6--34.7                 94.3 (Nepal)                                               

  Coverage rate with the first dose of a measles-containing-vaccine (MCV1) among one-year-olds (%)                                    169          93\                        30 (Equatorial Guinea)\                0.3851              0.7095
                                                                                                                                                   84--97                     99 (Mongolia and 23 other countries)                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IQR---interquartile range; GDP---gross domestic product; BMI---body mass index---weight (kg)/height (m)^2^; \* ^1^---adjusted for PCR tests per million population; \* ^2^---adjusted for PCR tests and COVID-19 morbidity per million population; \* ^3^---number of countries the data were able to abstract, \*: *p* \< 0.001. Bold letters mean statistically significant: *p* \< 0.001.
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###### 

Factors associated with morbidity adjusted for PCR-test rates.

  Variable                                   Coef.   Std. Err.   *p*-Value   95% CI           Adjusted R^2^
  ------------------------------------------ ------- ----------- ----------- ---------------- ---------------
  PCR-tests per million population (log10)   0.574   0.101       \<0.001     0.374 to 0.774   0.5037
  Urban population (%)                       0.764   0.329       0.02        0.113 to 1.416   
  Insufficient physical activity (%)         0.015   0.006       0.01        0.004 to 0.026   

Coef.---Coefficient; Std. Err.---Standard Error; 95% CI---95% confidence interval.
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###### 

Factors associated with mortality adjusted for morbidity and PCR-test rates.

  Variable                                   Coef.    Std. Err.   *p*-Value   95% CI             Adjusted R^2^
  ------------------------------------------ -------- ----------- ----------- ------------------ ---------------
  Morbidity per million population (log10)   1.342    0.067       \<0.001     1.210 to 1.475     0.8254
  PCR-tests per million population (log10)   −0.485   0.099       \<0.001     −0.680 to −0.290   
  Population ≥ 60 years of age (%)           0.030    0.010       0.003       0.011 to 0.050     
  BCG vaccine coverage                       −0.004   0.002       0.006       −0.007 to −0.001   
  Universal health coverage                  1.473    0.549       0.008       0.387 to 2.560     
  Medical doctors/10,000 population          0.003    0.004       0.47        −0.005 to 0.011    
  Elevated total cholesterol                 0.002    0.006       0.76        −0.010 to 0.014    
  HALE at age 60                             −0.03    0.029       0.27        −0.090 to 0.025    

HALE---healthy life expectancy, Coef.---Coefficient; Std. Err.---Standard Error; 95% CI---95% confidence interval.
